Thyroid cancer: clinical and histopathological features San Jose Hospital endocrinology department Bogota DC. 2000-2010

Cáncer de tiroides: características clínicas e histopatológicas Servicio de endocrinología, hospital de San José Bogotá dc, 2000-2010

Thyroid cancer is the most common head and neck malignancy. With a yearly incidence of 5% features a three-fold increase in females approaching their fifties, with more severe complications and relapse in old and in very young patients. Objectives: to describe the clinical and histologic/pathological characteristics of cases seen at the endocrinology department during 2000-2010. Method: case series in 199 clinical records of thyroid cancer. Results: the mean age at diagnosis was 40 years (13-75), 34.1% were older than 45 and 86.9% (n  173)  were females;  73.3% (n 146) felt a lump in the neck. Classical papillary carcinoma was found in 63.2% (n 126), followed by follicular carcinoma in 26.6% (n 53). The mean follow-up period was five months with an IQR of 2 to 18. In younger than 45 years of age patients relapse involved cervical lymph nodes in 60.8% (n 46). In older than 45, sixteen presented relapse, 56% involving lymph nodes and 37.5 % involving lung. Conclusions: as seen in other reports, thyroid cancer was more common in females in their fifties with classical papillary carcinoma. Relapses involved cervical lymph nodes and Iung. More severe clinical stages were associated with earlier relapses.

1. Davies L, Welch HG. Thyroid cancer survival in the United States: observational data from 1973 to 2005. Arch Otolaryngol Head Neck Surg. 2010;136(5):440-44.
2. Jeong M, Jin YW, Yang KH, Ahn YO, Cha CY. Radiation exposure and cancer incidence in acohortof nuclear powerindustryworkers in the Republic ofKorea, 1992-2005. Radial Environ Biophys. 2010;49(1):47-55.
Kronenberg H, Melmed S. Williams tratado de Endocrinología. ! la ed. Barcelona, España:Elsevier; 2008.
Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167-1214.
5. Layfield LJ, CibasES, Gharib H, Mande! SJ. Thyroid aspiration cytology: curren! status. CA Cancer J Clin. 2009 Mar-Apr; 59(2):99-110.
6. Sciuto R, Romano L, Rea S, Marandino F, Sperduti 1, Maini CL. Natural history and clinical outcomeof differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann Oncol. 2009;20(10):1728-35.
7. Haymart MR, Glinberg SL, Liu J, Sippel RS, Jaume JC, Chen H. Higher serurn TSH inthyroidcancerpatients occurs independent of age and correlates with extrathyroidal extension. ClinEndocrinol (Oxf). 2009;71(3):434-39.
8. W hitley RJ, Ain KB. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clin Lab Med. 2004;24(1):29-47.
9. Al-Saif O, Parrar WB, Bloomston M, Porter K, Ringel MD, K.loos RT. Long-term efficacy oflymphnode reoperation for persisten! papillary thyroid cancer. J Clin Endocrino! Metab. 2010;95(5):2187-94.
10. Gonzalez CC, Yaniskowski ML, Wyse EP, Giovannini AA, López MB, Wior ME. Cáncer de tiroides: estudio descriptivo retrospectivo. Medicina (Buenos Aires). 2006;66:526-32.
11. Gardner, D, Shoback, D. Greenspan basic clinical endoc1inology. 8ht ed. San francisco: McGraw hill; 2007.
12. Ito Y, Kakudo K, Hirokawa M et al. Biological behavior and prognosis of familia! papillary thyroid carcinoma. Surgery. 2009;145(1):100-05.
13. Kilfoy BA, Devesa SS, Ward MH et al. Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemial Biomarkers Prev. 2009;18(4): l 092-1100.
14. Garavito G. Factores pronósticos para la recaída en pacientes con cáncer papilar de tiroides. Rev. Col. Cancero!. 2005;9(2):21-30.
15. Torlontano M, Attard M, Crocetti U, Tumino S, Bruno R, Costante G. Follow-up of low 1isk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph metastases. J ClinEndocrino! Metab. 2004;89:3402-07.